HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2021-03-31 (expresspharma.in)
GSK Pharma board approves sale of Vemgal facility to Hetero Labs for Rs 180 crores
The transaction is expected to be completed by September 30, 2021
Read more
2021-03-31 (fiercepharma.com)
GlaxoSmithKline sells off $155M Zantac plant in India to Hetero Labs for a fraction of its cost
Three years ago, when it opened a $155 million plant in Vemgal, India, GlaxoSmithKline was anticipating a strong market for its gastroenterology treatments. | GlaxoSmithKline sold off an ambitious$ 155 million plant in Vemgal, India to domestic firm Hetero Labs just three years after it kicked off
Read more
(indiatimes.com)
GlaxoSmithKline Pharmaceuticals: GSK Pharma board approves sale of Vemgal plant to Hetero Labs, ET HealthWorld
GlaxoSmithKline Pharmaceuticals: The board of directors at its meeting held on Tuesday, approved the sale of the company's business undertaking i.e., manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka, to Hetero Labs Ltd.
Read more
(thehindubusinessline.com)
Ranitidine recall effect: GSK sells Karnataka plant to Hetero Labs for ₹180 cr
GlaxoSmithKline Pharmaceuticals Limited (GSK) said that its board of directors has approved the sale of its manufacturing facility at Vemgal (Karnataka) to Hetero Labs Limited for ₹180 crore.
Read more